<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897180</url>
  </required_header>
  <id_info>
    <org_study_id>NYADAGEORG</org_study_id>
    <nct_id>NCT02897180</nct_id>
  </id_info>
  <brief_title>Efficacy of Nyaditum Resae(R) Against Active TB in Georgia</brief_title>
  <official_title>Double-blind, Randomized, Masked, Placebo-controlled, Clinical Trial to Investigate the Efficacy of the Nutraceutical Nyaditum Resae(R) Administered to Contacts of Active Tuberculosis in Georgia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut Germans Trias i Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Tuberculosis and Lung Diseases (NCTLD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut Germans Trias i Pujol</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of a supplement food like &quot;Nyaditum resae&quot; is a reliable opportunity to stop the
      progression towards active TB through the most updated knowledge of this disease:the
      induction of tolerance.

      In order to demonstrate the percentage of efficacy of this approach, different studies must
      be run to elucidate the percentage of protection in different setting all over the world. The
      strategy is to establish its efficacy through a simple clinical trial, aimed just to know the
      incidence of TB in Placebo and NR treated contacts of active TB cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of a supplement food &quot;Nyaditum resae&quot; in the uincidence of TB. This is a
      ranzomized doube-blind controlled clinical trial to evaluate the efficacy and safety of a
      supplememt food in comparison to placebo in TB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, incidence of confirmed cases of active TB</measure>
    <time_frame>2 years</time_frame>
    <description>The primary endpoint is to assess the incidence of active TB: confirmed TB cases (including extrapulmonary TB) as described as:
Clinical, radiology or histology evidence compatible with active TB plus validated Molecular Biology tests POSITIVE, or culture POSITIVE.
The GeneXpert MTB/RIF system will be used as molecular diagnostic test to identify M. tuberculosis in this trial. Although this, in case a patient is diagnosed using any other validated method (i.e.: diagnosed in a site not participating in the trial), this could be accepted if well documented Cultures will be done using validated methodologies, including both solid and liquid cultures.
An independent Endpoint Committee will be created to confirm all the TB cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy, incidence of all cases of active TB and mortality (all causes)</measure>
    <time_frame>2 years</time_frame>
    <description>1. Incidence of all TB: suspected and clinical active TB, defined as:
• Suspected active TB: Do not meet the confirmed criteria but have compatible Clinical or Radiological or Pathological examinations AND supportive Microbiology (AFB positive) or non-validated Molecular Biology positive evaluations.
• Clinical active TB: In the data collected, physician starts treatment without any supporting evidence of suspected or confirmed TB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events during the administration of the NR</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of adverse events in both arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to active TB</measure>
    <time_frame>2 years</time_frame>
    <description>Number of days to develop active TB</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Close Contacts of Active Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a total of 14 capsules with Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nyaditum resae(R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a total of 14 capsules with Nyaditum resae(R)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nyaditum resae(R)</intervention_name>
    <description>Capsules containing Nyaditum resae(R)</description>
    <arm_group_label>Nyaditum resae(R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containin Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have completed the written informed consent process prior to undergoing any screening
             evaluations.

          2. Have ability to complete follow-up period as required by the protocol.

          3. Willing to allow the investigators to discuss the subject's medical history with the
             subject's health care provider.

          4. Close contact of an active TB case not eligible for chemoprophylaxis.

        Exclusion Criteria:

          1. Investigator assessment of lack of understanding or willingness to participate and
             comply with all requirements of the trial protocol.

          2. Any other finding which in the opinion of the investigator would compromise the
             protocol compliance or significantly influence the interpretation of results on the
             effects of the vaccine.

          3. Being eligible for chemoprophylaxis (children of &lt;5 years old and HIV-positive adults)

          4. Pregnancy or lactation

          5. Hypersensitivity to mannitol

          6. Suffering active TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere-Joan Cardona, MD, PhD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacio Institut Germans Trias i Pujol (IGTP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pere-Joan Cardona, MD, PhD, Pr</last_name>
    <phone>+34934978686</phone>
    <email>pj.cardona@igtp.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cris Vilaplana, MD, PhD</last_name>
    <phone>+34934978677</phone>
    <email>cvilaplana@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nestani Tukvadze, MD</last_name>
      <email>marikushane@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <link>
    <url>http://www.manremyc.cat</url>
    <description>Manremyc is the company that produces Nyaditum resae</description>
  </link>
  <link>
    <url>http://unitatdetuberculosiexperimental.wordpress.com</url>
    <description>Experimental Tuberculosis Unit of the Germans Trias i Pujol website (PI's affiliation)</description>
  </link>
  <reference>
    <citation>Cardona P, Marzo-Escartín E, Tapia G, Díaz J, García V, Varela I, Vilaplana C, Cardona PJ. Oral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice. Front Microbiol. 2016 Jan 5;6:1482. doi: 10.3389/fmicb.2015.01482. eCollection 2015.</citation>
    <PMID>26779140</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>September 3, 2017</last_update_submitted>
  <last_update_submitted_qc>September 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>latent tuberculosis infection</keyword>
  <keyword>Food supplement</keyword>
  <keyword>Mycobacterium manresensis</keyword>
  <keyword>Nyaditum resae</keyword>
  <keyword>Efficacy trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

